Facebook Instagram X-twitter Linkedin

Cagrilintide (5mg)

Table of Contents

  • Quickstart Highlights

Cagrilintide (5mg) protocols center on this long-acting amylin analog studied for its potential to support appetite regulation, reduce caloric intake, and aid in body weight management. By mimicking the effects of endogenous amylin, Cagrilintide may promote satiety, slow gastric emptying, and improve metabolic control. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical dosing range: 0.25–1 mg per dose (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support appetite control and weight management via amylin receptor activation
  • Schedule: 1–2 injections per week due to extended half-life
  • Dose Range: 0.25–1 mg per administration
  • Dosing Protocol

Suggested approach for the 5 mg vial format.

  • Start: 0.25 mg once weekly to assess tolerance
  • Target: 0.5–1 mg once weekly
  • Frequency: Typically once weekly (subcutaneous)
  • Vial Duration: One 5 mg vial lasts approximately 5–20 doses, depending on dose
  • Timing: Flexible; maintain a consistent weekly schedule
  • Mechanism of Action

Cagrilintide is a synthetic, long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It binds to amylin receptors in the brain, particularly in areas involved in appetite regulation.

By activating these receptors, Cagrilintide may increase satiety signals, reduce hunger, and slow gastric emptying. This can lead to reduced food intake and improved glycemic control. It is often studied in combination with GLP-1 receptor agonists for enhanced weight management effects due to complementary mechanisms.

  • Potential Benefits & Side Effects

Observations based on clinical and early-stage research.

Potential Benefits:

  • May significantly reduce appetite and caloric intake
  • May support body weight reduction
  • May improve metabolic control when combined with other therapies
  • Long-acting profile allows less frequent dosing

Possible Side Effects:

  • Nausea (most common, especially during dose escalation)
  • Reduced appetite (intended effect, but may be pronounced)
  • Injection-site reactions
  • Long-term safety is still under evaluation; it remains investigational